SAN FRANCISCO--(BUSINESS WIRE)--Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has moved to further enhance its balance sheet via the acquisition of additional equity growth capital from several institutional and private investors. These funds will be used to accelerate the Company’s entry into the market for integrated optical biosensors targeting HIV/AIDS, malaria, tuberculosis, cholera and other pathogen detection and disease diagnosis.
